We are live on
!
Find out more
PM
Penbrook Management Portfolio holdings
AUM
$157M
1-Year Est. Return
46.57%
This Fund
S&P 500
This Quarter
Est. Return
+11.99%
1 Year Est. Return
+46.57%
3 Year Est. Return
+102.93%
5 Year Est. Return
+150.44%
10 Year Est. Return
–
AUM
$103M
AUM Growth
–
Cap. Flow
+$98.2M
Cap. Flow
% of AUM
95.28%
Top 10 Holdings %
Top 10 Hldgs %
26.91%
Holding
111
New
111
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVO
Novo Nordisk
NVO
|
+$4.43M |
| 2 |
Microsoft
MSFT
|
+$2.97M |
| 3 |
FEIC
FEI COMPANY
FEIC
|
+$2.86M |
| 4 |
Harvard Bioscience
HBIO
|
+$2.45M |
| 5 |
Calumet Specialty Products
CLMT
|
+$2.34M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 24.65% |
| 2 | Healthcare | 15.42% |
| 3 | Energy | 13.56% |
| 4 | Financials | 12.08% |
| 5 | Industrials | 6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
NVO
1
Novo Nordisk
NVO
$208B
| $4.69M | 4.55% |
+254,000
| New | +$4.43M |
|
|
2
Microsoft
MSFT
$3.62T
| $3.06M | 2.97% |
+81,744
| New | +$2.97M |
|
|
FEIC
3
DELISTED
FEI COMPANY
FEIC
| $2.88M | 2.79% |
+32,230
| New | +$2.86M |
|
4
Fidelity National Financial
FNF
$13.9B
| $2.67M | 2.59% |
+144,161
| New | +$2.33M |
|
|
5
Harvard Bioscience
HBIO
$28.5M
| $2.63M | 2.55% |
+56,001
| New | +$2.45M |
|
|
AFFX
6
DELISTED
Affymetrix Inc
AFFX
| $2.61M | 2.53% |
+304,500
| New | +$2.33M |
|
|
EPAY
7
DELISTED
Bottomline Technologies Inc
EPAY
| $2.47M | 2.39% |
+68,260
| New | +$2.21M |
|
8
Core Laboratories
CLB
$491M
| $2.33M | 2.26% |
+12,208
| New | +$2.27M |
|
|
SHOR
9
DELISTED
ShoreTel, Inc.
SHOR
| $2.21M | 2.15% |
+238,450
| New | +$1.8M |
|
|
10
Calumet Specialty Products
CLMT
$3.69B
| $2.17M | 2.11% |
+83,581
| New | +$2.34M |
|
11
Baytex Energy
BTE
$3.1B
| $2.08M | 2.02% |
+53,223
| New | +$2.14M |
|
|
PRCP
12
DELISTED
Perceptron Inc
PRCP
| $2.04M | 1.98% |
+147,058
| New | +$1.73M |
|
13
Alphabet (Google) Class C
GOOG
$4.56T
| $1.9M | 1.85% |
+68,175
| New | +$1.72M |
|
14
Moody's
MCO
$83.7B
| $1.9M | 1.84% |
+24,200
| New | +$1.77M |
|
15
Encore Capital Group
ECPG
$2.06B
| $1.85M | 1.79% |
+36,784
| New | +$1.75M |
|
16
Immersion
IMMR
$248M
| $1.8M | 1.74% |
+173,236
| New | +$2.12M |
|
|
LGCY
17
DELISTED
Legacy Reserves Inc. Common Stock
LGCY
| $1.76M | 1.71% |
+62,490
| New | +$1.72M |
|
18
Synopsys
SNPS
$75.1B
| $1.69M | 1.64% |
+41,650
| New | +$1.56M |
|
|
XCRA
19
DELISTED
Xcerra Corporation
XCRA
| $1.62M | 1.58% |
+203,284
| New | +$1.39M |
|
|
ARRS
20
DELISTED
ARRIS International plc Ordinary Shares
ARRS
| $1.52M | 1.48% |
+62,482
| New | +$1.19M |
|
|
IRBT
21
DELISTED
iRobot
IRBT
| $1.49M | 1.44% |
+42,700
| New | +$1.46M |
|
|
NUAN
22
DELISTED
Nuance Communications, Inc.
NUAN
| $1.47M | 1.43% |
+111,891
| New | +$1.54M |
|
23
Data I/O
DAIO
$30.4M
| $1.38M | 1.34% |
+537,250
| New | +$1.5M |
|
24
Teradyne
TER
$57.2B
| $1.34M | 1.3% |
+76,080
| New | +$1.29M |
|
|
VIVS
25
VivoSim Labs
VIVS
$1.17M
| $1.33M | 1.29% |
+500
| New | +$981K |
|
Similar funds
IWM
EP
AC
SF
LAM
HAM
HEM
CF
Penbrook Management's Q4 2013 Portfolio in Review
Q4 2013 is the first quarter with a 13F filing on record for Penbrook Management, which disclosed 111 positions worth $103M. Its ten largest holdings account for 27% of the portfolio.
Its largest position is Novo Nordisk: 254,000 shares worth $4.69M.
By sector, the portfolio is most concentrated in Technology at 25% of assets, followed by Healthcare and Energy.
- Penbrook Management's largest Q4 2013 buy was Novo Nordisk: 254,000 shares worth $4.69M.
- Penbrook Management's ten largest holdings make up 27% of its $103M portfolio in Q4 2013.
- Penbrook Management disclosed 111 positions in Q4 2013, its first 13F filing on record.
Based on Penbrook Management's 13F filing for Q4 2013, filed 25 Mar 2014.